Chimeric T-Cell Receptors for the Targeting of Cancer CellsRössig C. · Brenner M.K.
aUniversity Children’s Hospital Münster, Department of Pediatric Hematology and Oncology, Münster, Germany; bCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston, Tex., USA
Genetic engineering of human T lymphocytes to express tumor antigen-specific chimeric immune receptors is an attractive means for providing large numbers of effector cells for adoptive immunotherapy. Major mechanisms of tumor escape from immune recognition are efficiently bypassed. Although adoptive transfer of chimeric receptor-expressing peripheral blood-derived T lymphocytes has produced some anti-tumor activity in mice, the first clinical studies have revealed a disappointing lack of correlation between in vitro cytotoxicity and therapeutic efficacy. The most pertinent issue is that chimeric T cells fail to expand and rapidly lose their function in vivo. Potential strategies to enhance the therapeutic value of chimeric receptor-modified cells by preventing their functional inactivation in vivo are currently being investigated.
Claudia Rössig, MD
University Children’s Hospital Münster
Department of Pediatric Hematology and Oncology
Albert-Schweitzer-Strasse 33, DE–48149 Münster (Germany)
Tel. +49 251 8352819, Fax +49 251 8352804, E-Mail email@example.com
Number of Print Pages : 6
Number of Figures : 2, Number of Tables : 0, Number of References : 49
Affiliated with the ‘Molecular Biology of Hematopoiesis’ Symposia
Vol. 110, No. 2-3, Year 2003 (Cover Date: Released October 2003)
Journal Editor: I. Ben-Bassat, Tel Hashomer
ISSN: 0001–5792 (print), 1421–9662 (Online)
For additional information: http://www.karger.com/aha